Is this message not displayed correctly?
Please click here for the online version. |
|
Dear Readers,
The BIO International Convention 2025 in Boston was held under the motto "The world can’t wait" – a fitting theme that underscores the importance of biotechnology in addressing pressing global health and sustainability issues. In a time when political and economic challenges dominate the discussion, it was refreshing to see that science, innovation, and cooperation offer the right solutions. The major topics of our HealthCapital Berlin-Brandenburg cluster, such as artificial intelligence in life sciences and healthcare, cell and gene therapy, alternative methods to animal testing, techbio, women's health, and global health, also played a significant role in the conference program in Boston. Our exhibitors, including the IGES Institute, Pherion, Campus Berlin-Buch, Biotech Rabbit, Nio Health, Pharmtrace, and FyoniBio, were very satisfied with the outcomes and the numerous valuable discussions. Particularly noteworthy are the promising approaches discussed in conversations with international partners such as the Massachusetts Life Sciences Center, One Nucleus from the UK, or the international student network Nucleate. These encounters once again highlight the importance of transatlantic exchange for progress in the healthcare industry. Even though the sun doesn't always shine in Boston, the trip was well worth it. BIO 2025 demonstrated that we are strong together and that exchange and collaboration across borders are essential for our collective progress. Your
Dr. Kai Bindseil
Berlin Partner für Wirtschaft und Technologie |
|
Interview: Study highlights Charité’s economic importance Charité ranks among the world’s top hospitals — 6th globally in Newsweek’s 2024 list. But what about its economic impact? A new study by DIW Econ sheds light on this question. We spoke with Astrid Lurati, Charité’s CFO, about the findings — and some surprising insights.
Read more |
|
|
In portrait: the investor network Business Angels drive innovation with capital, expertise, and networks. The Berlin-Brandenburg Business Angels Club (BACB) celebrates strong growth, record investments, and a rising focus on healthcare. Its vision: more angel investors, more impact — especially in Berlin’s dynamic startup scene.
Read more |
|
|
Interview: How 3D printing is transforming healthcare From personalized medicine to bioprinted organs: Additive manufacturing is set to redefine the future of healthcare. In this interview, Naomi Nathan from MGA Medical explains how Berlin-Brandenburg is already leading the way — and why collaboration is key to unlocking the full potential of medical 3D printing.
Read more |
|
|
Interview: European test infrastructure for AI in healthcare AI is transforming healthcare — from robotic surgery to early disease detection. But how safe and trustworthy are these tools? TEF-Health, led by Prof. Dr. Petra Ritter (BIH at Charité), builds EU-wide testing infrastructure. In the interview, Ritter explains how the project works and why real-world validation is crucial.
Read more |
|
|
The tip from our relocation experts: Looking to get a feel for Berlin’s vibrant startup scene? The Berlin-Brandenburg Startup Map is your go-to tool to explore over 7,000 startups and ecosystem players across the city. Use it to discover who is working in your space, potential partners, investors, recent funding rounds and new talent. partners, investors, recent funding rounds and new talent. |
|
|
| You can filter by industry, funding stage and more or even add your own company to boost visibility. It is also a great way to see who is active in Berlin’s health and life sciences ecosystem - from digital health to biotech and medtech. Whether you are new to Berlin or already part of the scene, the map gives you a real-time overview of one of Europe’s most dynamic startup hubs. Contact us! Kerem Can Akkaya
Manager Biotech | Pharma
Berlin Partner for Business and Technology
📧 |
|
|
| | Berlin Demoday July 3, 2025 | Berlin Read more |
|
12th Annual HealthTech Investment Forum (HTIF) October 7, 2025 | Basel, Switzerland Read more |
|
25th Annual Biotech in Europe Forum October 8-9, 2025 | Basel, Switzerland
Read more |
|
World Health Summit 2025 October 12-14, 2025 | Berlin Read more |
|
ESMO Congress 2025 October 17-21, 2025 | Berlin Read more |
|
BIO-Europe 2025 November 3-5, 2025 | Vienna, Austria Read more |
|
Frontiers Health 2025 November 11-12, 2025 | Berlin Read more |
|
MEDICA 2025 November 17-20, 2025 | Düsseldorf Read more |
|
RegMed Forum 2026: Clinical translation of advanced therapeutic approaches February 19, 2026 | Berlin Read more |
|
For more events in the life science region Berlin-Brandenburg click here.
|
|
| AMBOSS closes €240 million financing round and expands its position as the leading co-pilot for physicians worldwide
AMBOSS, the leading resource for medical education and clinical decision-making in Germany and the US, closes a €240M financing round with new long-term investors, supporting the exploration of additional international markets and the expansion of its offering to nurses and other health care professionals.
Read more |
|
REMATIQ raises €5.4 million seed round to transform MedTech compliance with AI REMATIQ, the first AI-native platform for automated product compliance in MedTech, has raised €5.4 million in a seed funding round. The round is led by Project A Ventures, with participation from Amino Collective and HelloWorld, and complemented by renowned business angels such as SaaS founder Boris Lokschin (Spryker Systems) and industry veteran Timo Fleßner. Read more |
|
Eckert & Ziegler signs contract manufacturing agreement for Yttrium--90-based PentixaTher with Pentixapharm Eckert & Ziegler Radiopharma GmbH (EZR), a 100% subsidiary of Eckert & Ziegler SE, today announced the signing of a manufacturing agreement with Pentixapharm, a clinical-stage biopharmaceutical company. Under the terms of the agreement, EZR will produce and distribute patient-specific doses of Y90-PentixaTher, Pentixapharm’s lead CXCR4-targeting radiotherapeutic, for use in clinical trials. Read more |
|
| DMEA 2025 ends with record attendance and a boost for innovations in digital health care
Read more |
|
BIH partners with BioLabs to launch clinical incubator for biomedical translation of Advanced Therapy Medicinal Products (ATMPs) Read more |
|
Berlin-based blood analytics innovator aescolab secures new funding to advance data-driven employee health Read more |
|
Myalink platform improves care for patients with myasthenia gravis Read more |
|
Science and Technology News
|
|
|
Tumor diagnostics: AI model detects more than 170 types of cancer |
| The MRI image shows a brain tumor in an inauspicious location, – and a brain biopsy will entail high risks for the patient, who had consulted us due to double vision. Situations such as this case discussion, cited by way of example, in a multidisciplinary team of cancer medicine experts prompted researchers at Charité - Universitätsmedizin Berlin, together with cooperation partners, to look for new diagnostic procedures. The result is an AI model. The model makes use of specific characteristics in the genetic material of tumors – their epigenetic fingerprint, obtained for example from cerebrospinal fluid, among other things. As the team shows in the journal Nature Cancer*, the new model classifies tumors quickly and very reliably. |
|
|
|
S100A1 identified as potential new biomarker for frailty in older patients with heart disease Frailty is a condition characterized by increased vulnerability and decline in physical function. It is a growing concern in the aging population, particularly among those with heart disease. A multidisciplinary research team led by the German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), the Faculty of Health Sciences (FGW) at the University of Potsdam and Deutsches Herzzentrum der Charité has now identified the gene S100A1 as a potential biomarker and therapeutic target in muscle tissue of older patients with heart disease, offering the potential to counteract mobility loss and muscle weakness early on. The findings were published in the Journal of Cachexia, Sarcopenia and Muscle.
Read more |
|
Joint Berlin Data & AI Center planned
Data-driven research is crucial for tackling societal challenges. In a collaboration that is so far unique, Berlin's Universities of Excellence, the Max Delbrück Center, and the Helmholtz-Zentrum Berlin, together with the Zuse Institute Berlin, aim to establish a powerful Data and AI Center.
Read more |
|
Preventing chronic inflammation from turning into cancer
Read more |
|
Consortium of African and European research institutions secures €1.5 million grant to build capacity for early drug discovery in sub-Saharan Africa Read more |
|
Charité study yields new data on Mpox vaccine effectiveness Read more |
|
Amino acid profiles as biomarkers for muscle health in older people Read more |
|
New findings on phage-antibiotic combination therapy Read more |
|
Technology and Cooperation Offers
|
|
|
Broad-spectrum antiviral compounds against known and emerging viruses
Read more |
|
Gene editing of the proteinase 3 autoantigen as a novel treatment for ANCA-associated vasculitis
Read more |
|
For more news from the cluster healthcare industries click here.
|
|
EDITOR | IMPRINT
This newsletter is operated by the cluster healthcare industries Berlin-Brandenburg HealthCapital.
Berlin Partner for Business and Technology
Fasanenstrasse 85 | 10623 Berlin | Germany
Phone: +49 30 46302-463
Email: healthcapital@berlin-partner.de
Commercial Registry Entry
Entered in the commercial registry of the Charlottenburg District Court,
Registration number: HRB 13072 B
VAT ID: DE 136629780
CEO: Dr. Stefan Franzke
Chairman of the Supervisory Board: Carsten Jung
Editorial: In cooperation with dpa-Custom Content.
Responsible body in terms of German Press Law
Carolin Meltendorf, Press Spokeswoman Berlin Partner for Business and Technology
© 2025 Berlin Partner for Business and Technology |
|
The newsletter of the Cluster healthcare industries Berlin-Brandenburg is a project of Berlin Partner for Business and Technology.
|
|
|
You have been forwarded this newsletter and would like to subscribe?
Please click here.
You want to unsubscribe from the newsletter (to: newsletter@newslettercollector.com)? Please click here. |
|
| |
|
